EXEL - Director At Exelixis Sells $576K Of Stock | Benzinga
A substantial insider sell was reported on May 23, by Julie Smith, Director at Exelixis (NASDAQ:EXEL), based on the recent SEC filing.
What Happened: Smith's recent Form 4 filing with the U.S. Securities and Exchange Commission on Thursday unveiled the sale of 27,280 shares of Exelixis. The total transaction value is $576,153.
Exelixis shares are trading down 0.0% at $20.41 at the time of this writing on Friday morning.
Unveiling the Story Behind Exelixis
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Exelixis: Financial Performance Dissected
Revenue Growth: Exelixis's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 4.02%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth ...